Host Hotels & Resorts Inc. Common Stock vs Novo Nordisk A/S — how do they compare? Host Hotels & Resorts Inc. Common Stock trades at $22.57 (market cap $15.44B), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 10.7× Host Hotels & Resorts Inc. Common Stock's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Host Hotels & Resorts Inc. Common Stock for 0 Days and Novo Nordisk A/S for 116 Days on average.
| HST | NVO | |
|---|---|---|
Market Cap | $15.44B | $165.31B |
Volume | 6,250,070 | 11,432,838 |
Sector | Real Estate | Health |
52-Week High | $25.54 | $63.98 |
52-Week Low | $15.82 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $19.13B | $179.56B |
Dividend Yield | 3.55% | 4.71% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Host Hotels & Resorts is a real estate investment trust that owns luxury and upscale hotel properties. Its portfolio includes hotels operated under major global brands.
Read more on HST →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →